A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Trial to Assess the Efficacy, Safety, and Tolerability of Centanafadine Extended-release Capsules as Monotherapy or as Adjunct to SSRI in Adult Subjects With Major Depressive Disorder
Latest Information Update: 04 Jun 2025
At a glance
- Drugs Centanafadine (Primary) ; Escitalopram (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms JUNIPER
- Sponsors Otsuka Pharmaceutical Development & Commercialization
Most Recent Events
- 30 May 2025 Status changed from recruiting to completed.
- 27 Mar 2025 Planned End Date changed from 14 Mar 2025 to 16 May 2025.
- 27 Mar 2025 Planned primary completion date changed from 14 Mar 2025 to 16 May 2025.